Emergent BioSolutions Inc. (NYSE:EBS) is pleased to announce the
appointment of Steven Chatfield, Ph.D. as Senior Vice President,
Biodefense effective immediately. Dr. Chatfield rejoins the Company
after recently serving as Executive Director of the U.K. Health
Protection Agency (HPA) and leading the Agency’s Centre for Emergency
Preparedness and Response. In his new position, Dr. Chatfield will play
a key role in the growth and development of Emergent’s biodefense
business, reporting directly to Daniel J. Abdun-Nabi, President and
Chief Operating Officer.
"We are delighted to welcome Dr. Chatfield back to the Emergent team,”
said Abdun-Nabi. "A leader of Steve’s stature and caliber, who brings
extensive experience from both industry and government, is truly an
asset in strengthening Emergent’s core biodefense business not only
within the U.S., but also in foreign markets, where we are expanding our
presence.”
With his knowledge of global biodefense issues and policies, Dr.
Chatfield will be an integral part of global initiatives in government
affairs, business development, and sales and marketing. He will be
responsible for interacting with various government entities as well as
representing the Company in scientific, investor, and business
conferences related to biodefense.
"My career has been devoted to developing and implementing strategies to
battle infectious diseases that have global unmet medical needs,” said
Dr. Chatfield. "To manage Emergent’s biodefense franchise, which
includes BioThrax® (Anthrax Vaccine Adsorbed), the only
vaccine licensed by the FDA against anthrax disease, and other product
candidates that could potentially protect against deadly pathogens,
gives me the opportunity to continue that mission of contributing to
safeguarding the health of the world’s population.”
For over 27 years, Dr. Chatfield has worked in the biopharmaceutical
industry and has been involved in all aspects of biopharmaceutical
research and development, with a particular focus on the development of
products to prevent and treat infectious disease. He is recognized
internationally as an opinion leader in the area of biotechnology and
has authored over 100 scientific papers in the field. Prior to joining
HPA, Dr. Chatfield was Chief Scientific Officer at Emergent as well as
President of Emergent Product Development U.K. from 2005 to 2007. He has
also held various positions in Microscience, Medeva PLC, Evans Medical,
Wellcome Biotechnology, and the Wellcome Foundation.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax
Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and
Drug Administration for the prevention of anthrax. Emergent’s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information
may be found at www.emergentbiosolutions.com
and www.biothrax.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including any potential future securities
offering, our expected revenue growth and net earnings for 2009, and any
other statements containing the words "believes”, "expects”,
"anticipates”, "plans”, "estimates” and similar expressions, are
forward-looking statements. There are a number of important factors that
could cause the company’s actual results to differ materially from those
indicated by such forward-looking statements, including appropriations
for BioThrax® procurement; our ability to obtain new BioThrax®
sales contracts; our plans to pursue label expansions and improvements
for BioThrax®; our plans to expand our manufacturing
facilities and capabilities; the rate and degree of market acceptance
and clinical utility of our products; the success of our ongoing and
planned development programs, preclinical studies and clinical trials;
and other factors identified in the company’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2009 and subsequent reports
filed with the SEC. The company disclaims any intention or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this press release.
